Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) ‘Focused on Adding Targeted IP’

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today provided an update on its intellectual property (“IP”) progress in support of its research and development strategy. According to the update, Cybin continues to prioritize the development of in-house IP and licensing opportunities that support its active development programs and future novel drug candidates. The company has more than 20 active patent filings — 14 of which were filed this year alone — across six patent families. Additionally, Cybin has entered into multiple licensing agreements that provide additional access to IP from over 15 more patents or patent applications. Collectively, through a combination of internal filings and licensing arrangements, the company has access to more than 35 patents and applications. “Securing and maintaining a robust IP portfolio is an important component of our approach to successful drug development,” said Cybin Chief Executive Officer Doug Drysdale. “We are focused on adding targeted IP that we believe complements our research and development strategy, supports our position as an innovator in the psychedelic therapeutics space, and will continue to build shareholder value.”

To view the full press release, visit https://ibn.fm/9RCoD

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

This entry was posted in Cybin Inc. CYBN. Bookmark the permalink.

Comments are closed.